Clinical Scorecard: A Machine Learning Model for Predicting Risk in Transthyretin Amyloid Cardiomyopathy
At a Glance
Category
Detail
Condition
Transthyretin cardiac amyloidosis (ATTR-CM), a progressive infiltrative cardiomyopathy caused by transthyretin amyloid fibril accumulation in the myocardium.
Key Mechanisms
Destabilized transthyretin tetramers dissociate into monomers and form amyloid fibrils; myocardial deposition increases ventricular stiffness and is associated with diastolic dysfunction, heart failure, and arrhythmias.
Target Population
Patients with confirmed ATTR-CM recruited from the Swiss Cardiac Amyloidosis Registry and the Cardiac Amyloidosis Registry at the Medical University of Vienna.
Care Setting
Multicenter registry study involving six Swiss tertiary centers and the Medical University of Vienna.
Key Highlights
The study aimed to develop and validate a model predicting a composite outcome of all-cause mortality or hospitalization for heart failure in patients with ATTR-CM.
The study used baseline clinical, laboratory, imaging, and genetic data.
The supplied excerpt does not report model performance results or provide enough detail to verify the modeling workflow.
Guideline-Based Recommendations
Diagnosis
In the study, light-chain amyloidosis was excluded before ATTR-CM was confirmed by technetium-labeled bone scintigraphy and/or endomyocardial biopsy.
Genetic testing was offered to every patient to distinguish wild-type from variant transthyretin amyloidosis.
Management
The article's background states that disease-modifying therapies have changed the natural history of ATTR-CM and provide a demonstrable survival advantage.
The study rationale describes prognostic stratification at diagnosis as relevant to treatment decision-making; it does not provide specific treatment recommendations.
Monitoring & Follow-up
Study follow-up assessments began 6 months after diagnosis and continued yearly.
The primary outcome was all-cause mortality or hospitalization for heart failure. Events were prospectively documented and, when available, corroborated with clinical records, hospitalization reports, or death notifications.
Risks
The source describes ATTR-CM as associated with progressive myocardial stiffness, diastolic dysfunction, heart failure, arrhythmias, cardiovascular events, and death.
The source reports median survival of approximately 20 to 66 months among untreated patient groups, varying by disease stage.
The authors state that established Mayo Clinic and NAC staging systems were developed before widespread use of disease-modifying therapies and may not adequately reflect risk trajectories among patients receiving contemporary treatment.
Patient & Prescribing Data
Patients with confirmed ATTR-CM enrolled in the Swiss Cardiac Amyloidosis Registry from February 2018 to November 2025 or the Medical University of Vienna registry from July 2014 to February 2025.
The excerpt states that disease-modifying therapies have changed the natural history of ATTR-CM and provide a demonstrable survival advantage. It provides no prescribing regimen, dose, or patient-level treatment results.
Clinical Best Practices
Study diagnostic criteria excluded light-chain amyloidosis before confirming ATTR-CM by technetium-labeled bone scintigraphy and/or endomyocardial biopsy.
Genetic testing was offered to distinguish wild-type from variant transthyretin amyloidosis.
The supplied excerpt does not describe enough modeling methods to verify the stated validation and training workflow.
by Giovanni Baj, Nicola Ciocca, Pooya Mohammadi Kazaj, Xuan Ma, Annina A. Studer Bruengger, Simon F. Stämpfli, Niklas F. Ehl, Sarah Hugelshofer, Otmar Pfister, Joëlle Lehmann, Christoph Ryffel, Lukas Hunziker, Michael Poledniczek, Andreas Kammerlander, George C. M. Siontis, Stephan Windecker, Moritz J. Hundertmark, Christian Nitsche, Isaac Shiri, Christoph Gräni
